Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN1201 in R/R CD19+/BCMA+ Hematologic Malignancies
NCT07113496Phase 1Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RN1201 in B cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), mature B-cell lymphoma and 1 more, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Treatment-Emergent Adverse Events up to 12 months and Dose-Limiting Toxicities. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
RN1201
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)multiple myeloma (MM)mature B-cell lymphomaplasmablastic lymphoma (PBL)
Beyond the preview
Go deeper on NCT07113496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07113496.